Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jenny C Yang

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Seminars in Respiratory and Critical Care Medicine|December 21, 2007
Optimizing use of quinolones in the critically illJenny C Yang, Brian T Tsuji, Alan Forrest
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 27, 2017
Reply to Ozaras et alMark S Sulkowski, Diana M Brainard, Jenny C Yang, et al.
The Journal of Antimicrobial Chemotherapy|April 11, 2008
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureusBrian T Tsuji, Jenny C Yang, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2012
A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteersLillian S L Ting, Jens Praestgaard, Nicole Grunenberg, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2008
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosaJürgen B Bulitta, Neang S Ly, Jenny C Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2016
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus InfectionMark S Sulkowski, Wan-Long Chuang, Jia-Horng Kao, et al.
Pharmacotherapy|December 1, 2010
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingLauren M Lim, Neang Ly, Dana Anderson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Antimicrobial Agents and Chemotherapy|March 10, 2010
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic modelJürgen B Bulitta, Jenny C Yang, Liliana Yohonn, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Seminars in Respiratory and Critical Care Medicine|December 21, 2007
Optimizing use of quinolones in the critically illJenny C Yang, Brian T Tsuji, Alan Forrest
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 27, 2017
Reply to Ozaras et alMark S Sulkowski, Diana M Brainard, Jenny C Yang, et al.
The Journal of Antimicrobial Chemotherapy|April 11, 2008
In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureusBrian T Tsuji, Jenny C Yang, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2012
A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteersLillian S L Ting, Jens Praestgaard, Nicole Grunenberg, et al.
Antimicrobial Agents and Chemotherapy|October 15, 2008
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosaJürgen B Bulitta, Neang S Ly, Jenny C Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2016
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus InfectionMark S Sulkowski, Wan-Long Chuang, Jia-Horng Kao, et al.
Pharmacotherapy|December 1, 2010
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingLauren M Lim, Neang Ly, Dana Anderson, et al.
Antiviral Therapy|October 25, 2017
Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitorEric Lawitz, Jenny C Yang, Luisa M Stamm, et al.
Antimicrobial Agents and Chemotherapy|March 10, 2010
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic modelJürgen B Bulitta, Jenny C Yang, Liliana Yohonn, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
Pageof 3